Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial. Stenmark Tullberg A, Thurfjell V, Kovacs A, Micke P, et al. Breast Cancer Res Treat 2025 Jun 9. doi: 10.1007/s10549-025-07744.

Read + Share

Amedeo Smart

Independent Medical Education

Stenmark Tullberg A, Thurfjell V, Kovacs A, Micke P, et al. Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial. Breast Cancer Res Treat 2025 Jun 9. doi: 10.1007/s10549-025-07744.
PMID: 40488800